Managing asthma in the era of biological therapies

Philip G. Bardin, David Price, Pascal Chanez, Marc Humbert, Arnaud Bourdin

► To cite this version:

Philip G. Bardin, David Price, Pascal Chanez, Marc Humbert, Arnaud Bourdin. Managing asthma in the era of biological therapies. *The Lancet Respiratory Medicine*, 2017, 5 (5), pp.376–378. 10.1016/S2213-2600(17)30124-8 . hal-01761925

HAL Id: hal-01761925

<https://hal.science/hal-01761925>

Submitted on 12 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Managing asthma in the era of biological therapies

Philip G. Bardin, David Price, Pascal Chanez, Marc Humbert, Arnaud Bourdin

► To cite this version:

Philip G. Bardin, David Price, Pascal Chanez, Marc Humbert, Arnaud Bourdin. Managing asthma in the era of biological therapies. *Lancet Respiratory medicine*, Elsevier, 2017, 5 (5), pp.376–378. 10.1016/S2213-2600(17)30124-8 . hal-01761925

HAL Id: hal-01761925

<https://hal.archives-ouvertes.fr/hal-01761925>

Submitted on 12 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Managing asthma in the era of biological therapies

Philip G Bardin , David Price , Pascal Chanez , Marc Humbert , Arnaud Bourdin

Asthma treatments have been remarkably successful at controlling symptoms. Up to 75% of people with asthma can achieve adequate asthma control on inhaled corticosteroids (ICS) with or without long-acting β 2-agonists (LABA).¹ But real-life studies have been sobering, indicating that full asthma control is only attained in about 30–40% of people with asthma.² Many patients retain impairment of lung function and poor quality of life.³

Suboptimal asthma control might occur for various reasons, but there is consensus that poor adherence with asthma medications is a cardinal cause.³ Studies have suggested that asthmatics are especially prone to lapse treatment during asymptomatic periods when having to take regular treatment interferes with their lifestyle. Patients also have concerns about long-term side-effects of ICS, and many choose to live with persistent asthma symptoms. Finally, since asthma is a disease characterised by chronic airway inflammation

with variable airflow limitation and unpredictable symptoms, treatment often requires frequent adjustment to achieve total control of chronic asthma. This aim might only be possible to attain in a small proportion of patients.

Improving adherence to asthma medication has proven difficult, despite educational strategies such as asthma management plans and simplified inhaler devices.³ For example, despite comprehensive educational asthma programmes targeting patients and general practitioners in countries like Australia, rates of adherence remain poor. There have also been schemes to educate patients about the long-term safety of ICS, but there remains considerable so-called corticophobia in the general population, and this is unlikely to change. Recognition of the key role of adherence has prompted novel approaches in other diseases. Introduction of directly-observed-therapy (DOT) in tuberculosis has resulted in improved

adherence with matching gains in cure rates.⁴ Whether this approach is applicable to asthma should perhaps be considered.

It can be argued that our current treatment paradigms for asthma are theoretical constructs that fail, at least in part, at a practical level. However, recent innovations might permit an alternative approach. First, asthma management has been improved by the implementation of maintenance and reliever therapy (MART) by use of an ICS–LABA combined inhaler. Patients are encouraged to use regular ICS and LABA but to augment inhaled treatment immediately when asthma symptoms flare. The strategy has been shown to reduce asthma exacerbations and lessen overall corticosteroid exposure.⁵ A recent non-industry funded, controlled study⁶ confirmed that MART had projected benefits on asthma exacerbations and corticosteroid exposure. MART has gradually gained acceptance worldwide as a feasible and working therapeutic option for asthma.⁷

A second important aspect is the successful development of biological drugs to optimally treat patients with severe asthma on the basis of disease phenotyping and biomarkers. Monoclonal antibody treatments such as anti-IgE, and more recently anti-IL-5, anti-IL-4, and anti-IL-13⁸ have shown their ability to treat so-called T2-related asthma. These studies have shown reductions in exacerbations and some improvements in lung function, asthma control, and quality-of-life outcomes. Most of the asthma population might be eligible for this kind of intervention. Importantly, these treatments can be administered at monthly intervals (or possibly longer) via subcutaneous injection and have minimal side-effects. They are therefore potentially suitable for strategies that implement DOT to improve adherence and disease control in asthma.

We therefore propose a new treatment paradigm for asthma. This approach has four steps (figure). First, people with asthma who are likely to respond to modulation of IgE, IL-5, IL-4, or IL-13 are identified. Second, daily ICS–LABA is replaced by biological therapy every month or every 2 months given as DOT. The patient’s general practitioner can do this step and establish the optimal rhythm of injection. Third, patients are educated to use ICS–LABA or long-acting muscarinic-antagonists (LAMA) on an as-needed

basis (MART) for flares of asthma symptoms. Finally, patients are monitored to ensure asthma control is maintained.

Could this overhaul of current asthma approaches work? Several lines of evidence suggest that it might improve current practice. The use of MART strategies has gained wide acceptance and although DOT has chiefly been used in tuberculosis, it appears suitable for application in a chronic disease such as asthma. Biological therapies have been effective and several compounds have shown efficacy with a reasonable safety profile. Finally, an analogous therapeutic approach using pre-seasonal omalizumab injections in children has been successful.⁹

However, there are important caveats. Substantial clinical research will be required to examine the effectiveness and feasibility of the proposal. Strategies to combine randomised studies with real-life pragmatic studies, not only in severe asthma but also in mild asthma, will be essential. Studies will also be needed to validate the overall strategy; examine

Figure: Proposed new asthma therapy scheme
Arrows represent mAb injections; red arrows indicate accessory injections. The red line represents ICS dose within triple fixed combination therapy (supposing different ICS/LAMA/LABA combinations contain differing doses of ICS), and refers to the y axis, treatment pressure. During the total control phase, ICS dose is halved. Patients are then allowed to stop their regular, daily use of inhaled asthma medications (“triple”, which means association of ICS, LABA and LAMA in the same device) once total asthma control is achieved thanks to the mAb injections (controller triple withdrawal). These inhalers will be kept only for treating flare up, as a symptom reliever, on demand. During the flare-up phase, the daily dose of ICS in inhaled therapies increases. For both the blue and red line, dashes indicate that the length of time in which asthma symptoms are totally controlled is undetermined. mAb=monoclonal antibody. ICS=inhaled corticosteroids. LABA=long-acting β 2-agonists. LAMA=long-acting muscarinic-antagonists.

asthma outcomes, costs, and viability; identify patients with a treatable trait who will benefit;¹⁰ and substantiate acceptability to populations with asthma.

The potential benefits of reversing asthma treatment paradigms are evident: improved adherence, enhanced asthma control, fewer side-effects from ICS-LABA medications, simplified asthma management and greater convenience for patients. Indeed, regular anti-inflammatory treatment with biological therapies has the potential to reduce overall asthma severity. Since safety concerns have been satisfactorily addressed, cost considerations are likely to be the major limitation to their use. If this issue can be mitigated a reversal of current treatment algorithms might have substantial benefits and improve asthma management.

*Philip G Bardin, David Price, Pascal Chanez, Marc Humbert, *Arnaud Bourdin*

Monash Lung and Sleep, Monash Hospital and University, Clayton, VIC, Australia (PGB); Hudson Institute of Medical Research, Melbourne, Clayton, VIC, Australia (PGB); Observational and Pragmatic Research Institute, Singapore (DP); Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK (DP); UMR INSERM 1067, CNRS 7333, Marseille, France Aix-Marseille Université, Marseille, France (PC); APHM Assistance Publique Hôpitaux de Marseille, Clinique des bronches, de l'allergie et du Sommeil, Hôpital Nord, Marseille, France (PC); Service de Pneumologie, Assistance Publique—Hôpitaux de Paris, Hôpital Bicêtre, University Paris-Sud, Orsay, France (MH); Université Paris-Saclay, INSERM U999, Le Kremlin-Bicêtre, France (MH); Département de Pneumologie et Addictologie—Hôpital Arnaud de Villeneuve—Montpellier, France (AB); and PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France (AB)
a-bourdin@chu-montpellier.fr

AB was an investigator in clinical trials funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Cephalon, Chiesi, and Sanofi; participated in advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Teva, Sanofi, Chiesi, Roche, Regeneron, and Bioprojet; participated in Congresses with support of AstraZeneca, Actelion, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Chiesi, and PneumRx; and received unrestricted research funds from Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca. PGB has been an investigator in clinical trials funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Teva; participated in advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Novartis; attended Scientific Congresses with support of AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Menarini, and Novartis;

and received unrestricted research funds from GlaxoSmithKline, Teva and Novartis. PC has received consultancy fees for Almirall, Boehringer Ingelheim, Johnson & Johnson, GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Novartis, Teva, Chiesi, Sanofi, and SNCF; served on advisory boards for Almirall, Boehringer Ingelheim, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi, Schering Plough, and Sanofi; received lecture fees from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi, Boston Scientific, and ALK; and received industry-sponsored grants from Almirall, Boston Scientific, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, and Chiesi. MH reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Roche, and Teva. DP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (done through the Observational and Pragmatic Research Institute) from Aerocrine, AKL Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, Theravance, UK National Health Service, and Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva; payment for manuscript preparation from Mundipharma and Teva; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva, and Zentiva; stock or stock options from AKL Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute, Singapore; and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, HTA, and Medical Research Council.

- 1 Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. *Am J Respir Crit Care Med* 2004; **170**: 836–44.
- 2 Reddel HK. Treating according to asthma control: does it work in real life? *Clin Chest Med* 2012; **33**: 505–17.
- 3 Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. *Eur Respir J* 2015; **46**: 622–39.
- 4 Karumbij, Garner P. Directly observed therapy for treating tuberculosis. *Cochrane Database Syst Rev* 2015; **12**: CD003343.
- 5 Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2013; **12**: CD009019.
- 6 Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. *Lancet Respir Med* 2013; **1**: 32–42.
- 7 Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? *J Allergy Clin Immunol* 2014; **133**: 39–41.
- 8 Dunn RM, Wechsler ME. Anti-interleukin therapy in asthma. *Clin Pharmacol Ther* 2015; **97**: 55–65.
- 9 Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. *J Allergy Clin Immunol* 2015; **136**: 1476–85.
- 10 Agustí A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. *Eur Respir J* 2016; **47**: 410–19.